Immunomedics Inc. (NASDAQ:IMMU)’s share price was down 1.8% during trading on Monday . The stock traded as low as $2.22 and last traded at $2.24, with a volume of 216,480 shares traded. The stock had previously closed at $2.28.

Several equities analysts have recently commented on IMMU shares. Jefferies Group raised shares of Immunomedics from a “hold” rating to a “buy” rating and increased their price target for the stock from $1.50 to $5.00 in a research report on Friday, May 6th. They noted that the move was a valuation call. Zacks Investment Research raised shares of Immunomedics from a “hold” rating to a “buy” rating and set a $3.00 price target on the stock in a research report on Tuesday, April 5th. Finally, Wells Fargo & Co. reaffirmed a “buy” rating on shares of Immunomedics in a research report on Tuesday, May 24th.

The firm’s market cap is $219.00 million. The stock has a 50-day moving average price of $2.88 and a 200 day moving average price of $2.77.

Immunomedics (NASDAQ:IMMU) last issued its quarterly earnings data on Wednesday, May 4th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.13) by $0.02. Equities analysts expect that Immunomedics Inc. will post ($0.57) EPS for the current fiscal year.

In other Immunomedics news, CEO Cynthia L. Goldenberg sold 63,959 shares of the stock in a transaction on Monday, June 6th. The shares were sold at an average price of $4.09, for a total value of $261,592.31. Following the completion of the sale, the chief executive officer now owns 703,029 shares in the company, valued at $2,875,388.61. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Chairman David M. Goldenberg sold 12,300 shares of the stock in a transaction on Tuesday, June 7th. The shares were sold at an average price of $3.98, for a total transaction of $48,954.00. Following the completion of the sale, the chairman now owns 2,602,063 shares of the company’s stock, valued at approximately $10,356,210.74. The disclosure for this sale can be found here.

An institutional investor recently bought a new position in Immunomedics stock. Marshall Wace LLP purchased a new position in Immunomedics Inc. (NASDAQ:IMMU) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 857,062 shares of the biopharmaceutical company’s stock, valued at approximately $2,631,000. Marshall Wace LLP owned 0.90% of Immunomedics as of its most recent SEC filing.

Immunomedics, Inc is a clinical-stage biopharmaceutical company developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. The Company’s technologies allow it to create humanized antibodies in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.